1 STATE OF OKLAHOMA
1
2 2nd Session of the 59th Legislature (2024)
2
3 SENATE BILL 1943 By: Paxton
3
4
4
5
5
6 AS INTRODUCED
6
7 An Act relating to the Uniform Controlled Dangerous
7 Substances Act; amending 63 O.S. 2021, Section 2-303,
8 as amended by Section 1, Chapter 31, 1st
8 Extraordinary Session, O.S.L. 2023 (63 O.S. Supp.
9 2023, Section 2-303), which relates to registration;
9 removing ability for persons to be initially
10 permitted and certain fees associated with
10 registration; providing for promulgation of rules;
11 and providing an effective date.
11
12
12
13
13
14 BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
14
15 SECTION 1. AMENDATORY 63 O.S. 2021, Section 2-303, as
15
16 amended by Section 1, Chapter 31, 1st Extraordinary Session, O.S.L.
16
17 2023 (63 O.S. Supp. 2023, Section 2-303), is amended to read as
17
18 follows:
18
19 Section 2-303. A. The Director of the Oklahoma State Bureau of
19
20 Narcotics and Dangerous Drugs Control shall register an applicant to
20
21 own a medical facility as described in subsection C of Section 2-302
21
22 of this title, or to manufacture, distribute, dispense, prescribe,
22
23 administer or use for scientific purposes controlled dangerous
23
24 substances included in Schedules I through V of Section 2-101 et
24
Req. No. 2647 Page 1
 1 seq. of this title unless the Director determines that the issuance
1
2 of such registration is inconsistent with the public interest. In
2
3 determining the public interest, the following factors shall be
3
4 considered:
4
5 1. Maintenance of effective controls against diversion of
5
6 particular controlled dangerous substances and any Schedule I or II
6
7 substance compounded therefrom into other than legitimate medical,
7
8 scientific or industrial channels including examination of the
8
9 fitness of his or her employees or agents to handle dangerous
9
10 substances;
10
11 2. Compliance with applicable state and local law;
11
12 3. Has been found guilty of, entered a plea of guilty or nolo
12
13 contendere to a charge under the Uniform Controlled Dangerous
13
14 Substances Act or any other state or federal law relating to any
14
15 substance defined herein as a controlled dangerous substance or any
15
16 felony under the laws of any state or the United States;
16
17 4. Furnishing by the applicant false or fraudulent material
17
18 information in any application filed under Section 2-101 et seq. of
18
19 this title;
19
20 5. Past experience in the manufacture, distribution,
20
21 dispensing, prescribing, administering or use for scientific
21
22 purposes of controlled dangerous substances, and the existence in
22
23 the establishment of effective controls against diversion;
23
24
24
Req. No. 2647 Page 2
 1 6. Denial, suspension or revocation of the applicant’s federal
1
2 registration to manufacture, distribute or dispense controlled
2
3 dangerous substances as authorized by federal law; and
3
4 7. Such other factors as may be relevant to and consistent with
4
5 the public health and safety.
5
6 Nothing herein shall be deemed to require individual licensed
6
7 pharmacists to register under the provisions of the Uniform
7
8 Controlled Dangerous Substances Act.
8
9 B. Registration granted under subsection A of this section
9
10 shall not entitle a registrant to manufacture, distribute, dispense,
10
11 prescribe, administer or use for scientific purposes controlled
11
12 dangerous substances in Schedule I or II other than those specified
12
13 in the registration.
13
14 C. Practitioners shall be registered to dispense, prescribe,
14
15 administer or use for scientific purposes substances in Schedules II
15
16 through V if they are authorized to carry on their respective
16
17 activities under the laws of this state. A registration application
17
18 by a practitioner who wishes to conduct research with Schedule I
18
19 substances shall be accompanied by evidence of the applicant’s
19
20 federal registration to conduct such activity and shall be referred
20
21 to the Medical Research Commission for advice. The Medical Research
21
22 Commission shall promptly advise the Director concerning the
22
23 qualifications of each practitioner requesting such registration.
23
24 Registration for the purpose of bona fide research or of use for
24
Req. No. 2647 Page 3
 1 scientific purposes with Schedule I substances by a practitioner
1
2 deemed qualified by the Medical Research Commission may be denied
2
3 only on a ground specified in subsection A of Section 2-304 of this
3
4 title or if there are reasonable grounds to believe that the
4
5 applicant will abuse or unlawfully transfer such substances or fail
5
6 to safeguard adequately such applicant’s supply of such substances
6
7 against diversion from legitimate medical or scientific use.
7
8 D. 1. The Director shall initially permit persons to register
8
9 who own or operate any establishment engaged in the manufacture,
9
10 distribution, dispensing, prescribing, administering or use for
10
11 scientific purposes of any controlled dangerous substances prior to
11
12 June 4, 1991, and who are registered or licensed by the state. Fees
12
13 for registration under this section shall be as follows:
13
14 Practitioners and mid-level
14
15 practitioners $140.00 per year
15
16 of registration
16
17 Home Care Agencies, Hospices &
17
18 Home Care Services $140.00 annually
18
19 Medical Facility Owners $300.00 annually
19
20 Distributors $300.00 annually
20
21 Manufacturers $2,500.00 annually
21
22 Manufacturer, Wholesaler, or
22
23 Distributor of drug products
23
24
24
Req. No. 2647 Page 4
 1 containing pseudoephedrine
1
2 or phenylpropanolamine $300.00 annually
2
3 2. A registrant shall be required to pay double the amount of
3
4 the above-listed fee for any renewal of registration received more
4
5 than thirty (30) days late.
5
6 3. A Ten Dollar ($10.00) fee shall be charged for a duplicate
6
7 registration certificate.
7
8 E. Compliance by manufacturers and distributors with the
8
9 provisions of the Federal Controlled Substances Act, 21 U.S.C.,
9
10 Section 801 et seq., respecting registration, excluding fees, shall
10
11 be deemed sufficient to qualify for registration under Section 2-101
11
12 et seq. of this title.
12
13 F. The Director shall promulgate rules necessary for
13
14 registration application periods.
14
15 SECTION 2. This act shall become effective November 1, 2024.
15
16
16
17 59-2-2647 MR 1/18/2024 12:21:51 PM
17
18
18
19
19
20
20
21
21
22
22
23
23
24
24
Req. No. 2647 Page 5